Gene symbol: MIR339

Also known as: MIRN339; mir-339; hsa-mir-339

Organism: Homo sapiens

Summary: microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009]

NCBI gene ID: 442907 Ensembl:ENSG00000199023 MIM:615977 miRBase:MI0000815 AllianceGenome:HGNC:31776


Expression profile of MIR339 in omics data



ID GSE166193
Title Expression data from human astrocytes (HA) under oxygen-glucose deprivation / reoxygenation
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5065655 without DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 0 h tissue: brain 7.3275
GSM5065656 without DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 2 h tissue: brain 7.15735
GSM5065657 without DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 6 h tissue: brain 7.2326
GSM5065658 without DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 12 h tissue: brain 7.1691
GSM5065659 without DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 24 h tissue: brain 7.09913
GSM5065660 with DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 0 h tissue: brain 7.15872
GSM5065661 with DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 2 h tissue: brain 7.38885
GSM5065662 with DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 6 h tissue: brain 7.10393
GSM5065663 with DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 12 h tissue: brain 7.32913
GSM5065664 with DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 24 h tissue: brain 7.34279
GSM5065665 control cell type: astrocyte treatment: without stress tissue: brain 7.17001

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 5.346676452
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 4.650953141
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 4.633875772
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 4.802589951
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 4.828522191
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 4.649438472

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 3.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 3.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 1.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 6.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 1.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 5.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 4.59188
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 4.06093
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 4.43131
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 4.3175
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.60424
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.41781
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.58946
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.7159
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.91439
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.51028
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.47344
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.40054
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 4.5214
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 4.59513
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.28994
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.25275
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.33226
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.16813
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.83132
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.94449
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 4.42455
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 4.39105
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.97878
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.42664
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.12166
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.28804
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.84043
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.62118
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.31373
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.65086
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.27372
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.2673
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.0723
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.65829
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.07303
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.0157
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.24662
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.35368
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 4.07961
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.79082
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.99199
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.36786
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 4.83616
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.95845
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 4.49039
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 4.21196
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.33221
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.91346